Women Have Lower Relative Survival After Bladder Cancer Diagnosis
In a study, women with bladder cancer had approximately 1.5-fold higher mortality than men — but only in the short term.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Should Age Be a Barrier to Clinical Trial Participation for Older Patients With Metastatic Renal Cell Carcinoma?
A retrospective study compared older patients with mRCC with younger ones to determine if age and potential comorbidities is a barrier to clinical trial participation.
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Elevated NLR Combined With Low Sodium Predicts Worse Survival in RCC
At RCC diagnosis, patients with an neutrophil-lymphocyte ratio (NLR) above 3.0 and concomitant hyponatremia had a significant 2.8-fold increased risk of death compared with those who had an NLR of 3.0 or lower and normal sodium levels, a Danish study found.
Axitinib Did Not Meet Study End Point in mRCC, but Dosing Found Feasible
Although study failed to meet its primary endpoint, the researchers suggest approach could be used in clinical practice.
Robotic Partial Cystectomy Does Not Hike Positive Surgical Margin Risk
Investigators report finding no significant difference in positive surgical margin rates among open, laparoscopic, and robotic-assisted approaches to partial cystectomy.
Delayed RC for Histologic Variant Urothelial Bladder Cancer Ups Death Risk
Each 1-month delay in radical cystectomy following diagnosis of variant histology urothelial carcinoma of the bladder was associated with a 36% increased risk of death, a study found.
Robotic, Open Cystectomy for Bladder Cancer Offer Comparable Outcomes
In a propensity score matched analysis, robotic-assisted and open radical cystectomy for urothelial bladder cancer did not differ significantly with respect to disease recurrence and cancer-specific mortality rates.
Right-Sided RCC Predicts Better Outcomes in Patients With Larger Tumors
Among patients undergoing surgery for 10 cm or larger renal cell carcinoma tumors, right-sided tumors are independently associated with improved cancer-specific survival compared with left-sided tumors, a study found.
Combo Shows Promise as Alternative for Metastatic Urothelial Carcinoma
In a phase 2 trial, a regimen of gemcitabine plus eribulin compared favorably with other regimens for the first-line treatment of cisplatin-ineligible patients with metastatic urothelial carcinoma.
UTUC With Isolated Lymph Node Involvement Predicts Poor Survival
Patients who undergo surgical resection of nonmetastatic upper tract urothelial carcinoma with isolated lymph node involvement have a 5-year overall survival rate of only 24%, a study found.
Upfront Immune Checkpoint Inhibition Called New Metastatic RCC Standard of Care
Updated European Association of Urology guidelines recommend pembrolizumab plus axitinib or ipilimumab plus nivolumab for the first-line treatment of metastatic clear-cell renal cell carcinoma.
Nivolumab Shows Long-Term Survival Benefit in RCC, Other Cancers
In a post hoc analysis of a phase 1 trial, nivolumab treatment was associated with long-term survival in a subset of patients with advanced renal cell carcinoma, melanoma, and non-small cell lung cancer.
Guideline-Based Hematuria Evaluation May Up Risk of Secondary Cancers
Uniform use of computed tomography for hematuria workups marginally increases detection of urinary tract cancers while raising the risk for secondary cancers from imaging-associated radiation, researchers concluded.
Cryoablation vs PN for pT1b RCC Predicts Greater Cancer Death Risk
Among patients with pT1b renal cell carcinoma, cryoablation is associated with a 2.5-fold higher 5-year cancer-specific mortality rate compared with partial nephrectomy, a study found.
Erdafitinib Achieves 40% Response Rate in Advanced Urothelial Cancers
In a phase 2 trial, erdafitinib demonstrated measurable antitumor activity in 40% of patients with FGFR3-mutant advanced urothelial cancers, investigators reported.
Time on mRCC Drug Linked to Survival
Within the first 2 lines of treatment, patients with metastatic renal cell carcinoma who remain on a drug for at least 3 months have longer overall survival than those who do not, a study found.
Biosimilars Mvasi, Kanjinti Now Available in the US
Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.
Frailty Predicts Higher In-Hospital Mortality After Radical Cystectomy
Frail patients are more likely than non-frail patients to experience adverse perioperative outcomes after radical cystectomy, a study found.
RCC Ablation Technique Influences Survival Time
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Want to read more?
Please login or register first to view this content.
